vs
车车集团（CCG）与KESTRA MEDICAL TECHNOLOGIES, LTD.（KMTS）财务数据对比。点击上方公司名可切换其他公司
车车集团的季度营收约是KESTRA MEDICAL TECHNOLOGIES, LTD.的1.5倍（$32.8M vs $22.6M），车车集团净利率更高（0.5% vs -145.3%，领先145.8%）
车车集团是国内领先的汽车数字化服务提供商，主营汽车保险中介服务、智能汽车售后支持、车联网技术产品等业务，服务覆盖个人车主、汽车经销商及保险合作机构，部分业务辐射东南亚市场。
Kestra Medical Technologies（KMTS）是一家专注于微创医疗器械研发、生产与商业化的医疗科技企业，核心产品覆盖介入心脏病学与结构性心脏病治疗领域，市场覆盖北美、欧洲及亚太重点区域，服务全球医疗机构与患者。
CCG vs KMTS — 直观对比
营收规模更大
CCG
是对方的1.5倍
$22.6M
净利率更高
CCG
高出145.8%
-145.3%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $32.8M | $22.6M |
| 净利润 | $153.6K | $-32.8M |
| 毛利率 | 5.7% | 50.6% |
| 营业利润率 | — | -140.7% |
| 净利率 | 0.5% | -145.3% |
| 营收同比 | — | — |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.00 | $-0.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCGKMTS
| Q1 26 | $32.8M | — | ||
| Q4 25 | — | $22.6M | ||
| Q3 25 | — | $19.4M | ||
| Q2 25 | $26.0M | — | ||
| Q4 24 | $18.6M | — | ||
| Q2 24 | $36.1M | — |
净利润CCGKMTS
| Q1 26 | $153.6K | — | ||
| Q4 25 | — | $-32.8M | ||
| Q3 25 | — | $-25.8M | ||
| Q2 25 | $-492.4K | — | ||
| Q4 24 | $-196.7K | — | ||
| Q2 24 | $-7.6M | — |
毛利率CCGKMTS
| Q1 26 | 5.7% | — | ||
| Q4 25 | — | 50.6% | ||
| Q3 25 | — | 45.7% | ||
| Q2 25 | 4.9% | — | ||
| Q4 24 | 5.2% | — | ||
| Q2 24 | 4.3% | — |
营业利润率CCGKMTS
| Q1 26 | — | — | ||
| Q4 25 | — | -140.7% | ||
| Q3 25 | — | -149.1% | ||
| Q2 25 | -2.0% | — | ||
| Q4 24 | -0.3% | — | ||
| Q2 24 | -4.7% | — |
净利率CCGKMTS
| Q1 26 | 0.5% | — | ||
| Q4 25 | — | -145.3% | ||
| Q3 25 | — | -133.3% | ||
| Q2 25 | -1.9% | — | ||
| Q4 24 | -1.1% | — | ||
| Q2 24 | -21.0% | — |
每股收益（稀释后）CCGKMTS
| Q1 26 | $0.00 | — | ||
| Q4 25 | — | $-0.64 | ||
| Q3 25 | — | $-0.50 | ||
| Q2 25 | $-0.01 | — | ||
| Q4 24 | $-0.00 | — | ||
| Q2 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $20.0M | $175.4M |
| 总债务越低越好 | $193.3K | — |
| 股东权益账面价值 | — | $164.1M |
| 总资产 | $203.5M | $246.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CCGKMTS
| Q1 26 | $20.0M | — | ||
| Q4 25 | — | $175.4M | ||
| Q3 25 | — | $201.2M | ||
| Q2 25 | $23.1M | — | ||
| Q4 24 | $21.1M | — | ||
| Q2 24 | $28.2M | — |
总债务CCGKMTS
| Q1 26 | $193.3K | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $690.0K | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — |
股东权益CCGKMTS
| Q1 26 | — | — | ||
| Q4 25 | — | $164.1M | ||
| Q3 25 | — | $184.2M | ||
| Q2 25 | $47.1M | — | ||
| Q4 24 | $49.1M | — | ||
| Q2 24 | $48.6M | — |
总资产CCGKMTS
| Q1 26 | $203.5M | — | ||
| Q4 25 | — | $246.7M | ||
| Q3 25 | — | $266.3M | ||
| Q2 25 | $177.3M | — | ||
| Q4 24 | $177.7M | — | ||
| Q2 24 | $139.3M | — |
负债/权益比CCGKMTS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.01× | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-18.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-25.6M |
| 自由现金流率自由现金流/营收 | — | -113.5% |
| 资本支出强度资本支出/营收 | — | 32.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CCGKMTS
| Q1 26 | — | — | ||
| Q4 25 | — | $-18.3M | ||
| Q3 25 | — | $-26.3M | ||
| Q2 25 | $-44.7M | — | ||
| Q4 24 | $-15.8M | — | ||
| Q2 24 | $-1.0K | — |
自由现金流CCGKMTS
| Q1 26 | — | — | ||
| Q4 25 | — | $-25.6M | ||
| Q3 25 | — | $-34.4M | ||
| Q2 25 | — | — | ||
| Q4 24 | $-16.0M | — | ||
| Q2 24 | $-1.1K | — |
自由现金流率CCGKMTS
| Q1 26 | — | — | ||
| Q4 25 | — | -113.5% | ||
| Q3 25 | — | -177.8% | ||
| Q2 25 | — | — | ||
| Q4 24 | -85.9% | — | ||
| Q2 24 | -0.0% | — |
资本支出强度CCGKMTS
| Q1 26 | — | — | ||
| Q4 25 | — | 32.2% | ||
| Q3 25 | — | 42.2% | ||
| Q2 25 | — | — | ||
| Q4 24 | 1.2% | — | ||
| Q2 24 | 0.0% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
